Unknown PHASE4 INTERVENTIONAL 1-arm NCT03633019

High-dose Use of rhTPO in CIT Patients (HUrhTPOCITP)

High-dose Use of Recombinant Human Thrombopoietin in Patients With Moderate or Severe Thrombocytopenia Induced by Chemotherapy

Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Conditions Thrombocytopenia

Interventions rhTPO

Updated 6 times since 2018 Last updated: Oct 28, 2018 Started: Sep 28, 2018 Primary completion: Nov 30, 2019 Completion: Dec 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Thrombocytopenia, this trial is ongoing. The trial is conducted by First Affiliated Hospital Xi'an Jiaotong University and has accumulated 6 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Feb 2021 — Jul 2024 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE4
Nov 2018 — Jan 2021 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Sep 2018 — Nov 2018 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

First Affiliated Hospital Xi'an Jiaotong University
Shenyang Pharmaceutical University

Data source: First Affiliated Hospital Xi'an Jiaotong University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xi'an, China